No. |
DrugBank |
薬物名(臨床試験情報から抽出) |
KEGG DRUG * | KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 | 7-beta-Hydroxyepiandrosterone | 1件: 7-beta-hydroxyepiandrosterone; | - |
- |
- |
1件: 6 |
2 | ACR325 | 1件: Acr325; | - |
- |
- |
1件: 6 |
3 | AV-101 | 1件: Av-101; | - |
- |
- |
1件: 6 |
4 | Acamprosate | 1件: Acamprosate; | D02780 D07058 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
2件: 6, 206 |
5 | Acetaminophen | 8件: Acetaminophen; Acetaminophen tab 650mg; Acetaminophen tablets; Acetaminophen/paracetamol; Oxycodone/acetaminophen; Paracetamol (acetaminophen); Tramadol /acetaminophen; Tramadol hydrochloride + acetaminophen; | D00217 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
13件: 3, 6, 13, 34, 35, 46, 49, 51, 70, 86, 231, 256, 271 |
6 | Acetate | 76件: 11c acetate; 11c-acetate; 20mg/0.5ml glatiramer acetate; 40 mg glatiramer acetate; [n-trans-3-hexenoyl] human growth hormone releasing factor (1-44) acetate; Abiraterone acetate; Acetate; Bazedoxifene acetate; Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days; Caspofungin acetate; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cortisone acetate; Cosyntropin acetate; Cyclophosphamide/glatiramer acetate; Delmitide acetate; Depot leuprolide acetate 3.75 mg; Desmopressin acetate; Desmopressin acetate trihydrate; Dirucotide acetate; Experimental glatiramer acetate; Flecainide acetate; Glatiramer acetate; Glatiramer acetate (copaxone®); Glatiramer acetate (db); Glatiramer acetate (ga); Glatiramer acetate (ga) 40 mg; Glatiramer acetate (ol); Glatiramer acetate 150mg enteric coated tablets; Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets; Glatiramer acetate 20 mg; Glatiramer acetate 20 mg, with mitoxantrone; Glatiramer acetate 20 mg/0.5 ml; Glatiramer acetate 40 mg; Glatiramer acetate injection with oral cetirizine hydrochloride; Glatiramer acetate with minocycline; Glatiramer acetate, (copaxone®); Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b; Glatiramer acetate, n-acetylcysteine; Gonadorelin acetate and triptorelin acetate; Human interferon beta-1a and glatiramer acetate; Hydrocortisone sodium acetate; L-lysyl-d-prolyl-l-threonine acetate; Lanreotide acetate; Leuprolide acetate (la); Leuprolide acetate 11.25 mg; Leuprolide acetate 3 month depot; Leuprolide acetate 30 mg; Leuprolide acetate 45 mg; Leuprolide acetate depot; Leuprorelin acetate; Leuprorelin acetate 3.75mg injection; Loestrin (norethindrone acetate and ethinyl estradiol); Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol); Luphere depot 3.75mg(leuprolide acetate 3.75mg); Lupron (leuprolide acetate); Macimorelin acetate; Megestrol acetate; Megestrol acetate tablet; Nomegestrol acetate; Phosphate and betamethasone acetate, 2 ml.; Plovamer acetate; Prednisolone acetate; Prednisone acetate; Prednisone acetate tablets; Sodium acetate; Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate; Sotrastaurin (inn) acetate; Tetracosactide acetate; Tocopherol acetate; Tocopheryl acetate; Triptorelin acetate and gonadorelin acetate; Ulipristal acetate; Zinc acetate; Zinc acetate (20mg/d); Zinc acetate dihydrate; Zuretinol acetate; | - |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
7 | Acetylcysteine | 8件: Acetylcysteine; Acetylcysteine sodium; Glatiramer acetate, n-acetylcysteine; N acetylcysteine; N-acetylcysteine; N-acetylcysteine (nac); N-acetylcysteine capsule; N-acetylcysteine, (nac); | D00221 |
- |
- |
16件: 6, 13, 19, 20, 49, 51, 58, 85, 94, 96, 97, 111, 164, 233, 298, 299 |
8 | Activated charcoal | - | D03251 |
- |
- |
8件: 6, 13, 46, 85, 86, 96, 97, 298 |
9 | Ademetionine | - | D07128 |
- |
- |
15件: 6, 14, 22, 43, 44, 46, 47, 49, 50, 60, 84, 93, 96, 97, 172 |
10 | Agomelatine | 2件: Agomelatine; Agomelatine or piacebo; | D02578 |
3件: HTR2C, MTNR1A, MTNR1B |
6件: Calcium signaling pathway, Circadian entrainment, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse |
1件: 6 |
11 | Allopurinol | 4件: Allopurinol; Allopurinol sandoz 100 mg, tabletten; Allopurinol sodium; Azathioprine and allopurinol; | D00224 |
1件: XDH |
5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
6件: 6, 46, 57, 66, 96, 97 |
12 | Altropane | 2件: Altropane; Altropane®; | - |
- |
- |
1件: 6 |
13 | Amantadine | 10件: 240mg amantadine hcl er tablets; 320mg amantadine hcl er tablets; Ads-5102 (extended release amantadine hcl); Amantadine; Amantadine 300 mg; Amantadine hcl er; Amantadine hcl extended release; Amantadine hydrochloride; Amantadine sulfate; Pk-merz® 200mg/500ml inj(amantadine) , normal saline 500ml inj; | D00777 D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
4件: 6, 8, 13, 127 |
14 | Ambroxol | 2件: Ambroxol; Ambroxol hydrochloride; | D07442 |
- |
- |
2件: 6, 19 |
15 | Amoxicillin | 7件: Amoxicillin; Amoxicillin and tetracycline; Amoxicillin hydrate; Amoxicillin, metronidazole and tetracycline; Clartihromycin, amoxicillin, and omeprazole; Lansoprazole, amoxicillin, clarithromycin; Takecab tablets + amoxicillin + clarithromycin (first-line eradication) takecab tablets + amoxicillin + metronidazole (second-line eradication); | D00229 D02925 D07452 |
- |
- |
6件: 6, 46, 63, 96, 97, 222 |
16 | Aplindore | 2件: Aplindore; Aplindore mr tablets; | - |
- |
- |
1件: 6 |
17 | Apomorphine | 19件: 6abeta - apomorphine-10,11-diol hydrochloride hemihydrate; 6aß - apomorphine-10,11-diol hydrochloride hemihydrate; Apomorphine; Apomorphine 0.25% (2.5mg/ml); Apomorphine hcl injection; Apomorphine hydrochloride; Apomorphine hydrochloride 1.8mg inhalation powder, pre-dispensed; Apomorphine hydrochloride 2.8mg inhalation powder, pre-dispensed; Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed; Apomorphine hydrochloride 5.8 mg inhalation powder, pre-dispensed; Apomorphine hydrocloride; Apomorphine hydrocloride hemihydrate; Apomorphine infusion; Apomorphine nasal powder; Dopaminergic agonist + apomorphine; Injection of apomorphine; Iv apomorphine; S.c. apomorphine; Subcutaneous apomorphine; | D02004 D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
18 | Aripiprazole | 1件: Aripiprazole; | D01164 |
4件: DRD2, DRD3, HTR1A, HTR2A |
12件: Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
2件: 6, 206 |
19 | Armodafinil | 1件: Armodafinil; | D03215 |
1件: SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
3件: 6, 13, 84 |
20 | Atomoxetine | 1件: Atomoxetine; | D02574 D07473 |
1件: SLC6A2 |
1件: Synaptic vesicle cycle |
3件: 6, 8, 13 |
21 | Bavisant | 3件: Bavisant; Bavisant dihydrochloride monohydrate; Bavisant hydrochloride monohydrate; | D09870 |
1件: HRH3 |
1件: Neuroactive ligand-receptor interaction |
1件: 6 |
22 | Benserazide | 8件: Benserazide; Benserazide hydrochloride; Levodopa / benserazide 200 + 50 mg; Levodopa 100 mg / benserazide 25 mg; Levodopa benserazide madopar; Levodopa benserazide teva italia; Levodopa/benserazide; Levodopa/benserazide 100/25 mg; | D03082 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
23 | Benzofuran | 2件: Benzofuran; R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride; | - |
- |
- |
1件: 6 |
24 | Bifenthrin | - | - |
- |
- |
2件: 6, 46 |
25 | Botulinum Toxin Type B | 3件: Botulinum toxin type b; Botulinum toxin type b (2500 units / vial); Botulinum toxin type b (myobloc); | D02735 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
3件: 2, 6, 51 |
26 | Botulinum toxin type A | 3件: Botulinum toxin type a; Botulinum toxin type a (nabota®) injection into the gastrocnemius muscle; Clostridium botulinum toxin type a; | D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
13件: 2, 5, 6, 7, 13, 15, 17, 36, 51, 70, 113, 149, 226 |
27 | Bromocriptine | 2件: Bromocriptine; Bromocriptine and other dopamine agonists; | D00780 D03165 |
2件: DRD2, PRL |
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
2件: 6, 74 |
28 | Bumetanide | 2件: Bumetanide; Bumetanide white, oblong, scored tablet; | D00247 |
1件: SLC12A2 |
3件: Pancreatic secretion, Salivary secretion, Vibrio cholerae infection |
2件: 6, 158 |
29 | Buspirone | 2件: Buspirone; Buspirone hydrochloride; | D00702 D07593 |
2件: DRD2, HTR1A |
10件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
2件: 6, 51 |
30 | Butylphthalide | 1件: Butylphthalide; | - |
- |
- |
2件: 2, 6 |
31 | CEP-1347 | 5件: Cep-1347; Cep-1347 10mg; Cep-1347 50mg; Cep1347; Cep1347 25mg; | - |
- |
- |
1件: 6 |
32 | Cabergoline | 2件: Cabergoline; Pasireotide with or without cabergoline; | D00987 |
2件: DRD2, PRL |
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
3件: 6, 74, 75 |
33 | Caffeine | 5件: Caffeine; Caffeine 100 mg; Caffeine 100-200 mg bid; Caffeine alkaloid; Dextromethorphan and caffeine; | D00528 D01453 |
11件: ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A |
22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
6件: 2, 6, 46, 78, 96, 97 |
34 | Calcium | 25件: Amorphous calcium carbonate; Ascal(r) / carbasalate calcium; Atorvastatin calcium; Calcitriol & calcium; Calcium; Calcium and cholecalciferol; Calcium carbonate; Calcium carbonate and alphacalcidol; Calcium channel blockers; Calcium channel blockers (amlodipine, azelnidipine); Calcium citrate; Calcium citrate with vitamin d2; Calcium gluconate; Calcium lactate; Calcium levofolinate; Calcium rosuvastatin; Calcium, dietary; Carbasalate calcium; Crestor tablets (calcium rosuvastatin) film-coated tablets; Crystalline calcium supplements; Ibandronate+alfacalcidol+calcium; Low molecular weight heparin calcium injection; Rosuvastatin calcium; Symptomatic treatment (converting enzyme inhibitor, angiotensin ii, anti-renin, aldosterone antagonist diuretic, beta blocker, calcium inhibitor, statin); Vidofludimus calcium; | - |
- |
- |
24件: 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
35 | Cannabidiol | 6件: Cannabidiol; Cannabidiol (cbd); Cannabidiol / dronabinol capsule 5 mg+2,5 mg; Cannabidiol capsule 5 mg; Cannabidiol oral solution; Cannabidiol tablet 10 mg; | D10915 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
14件: 2, 6, 13, 46, 95, 96, 97, 140, 144, 145, 157, 158, 193, 271 |
36 | Capsaicin | 4件: Capsaicin; Capsaicin challenge; Capsaicin vapor; Qutenza (8% capsaicin); | D00250 |
1件: TRPV1 |
2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
6件: 2, 6, 19, 86, 113, 226 |
37 | Carbidopa | 60件: Accordion pill carbidopa/levodopa; Accordion pill™ carbidopa/levodopa; Accordion pill™ carbidopa/levodopa 50/400 mg; Accordion pill™ carbidopa/levodopa 50/500 mg; Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg); Carbidopa; Carbidopa 20 mg; Carbidopa 27.5 mg; Carbidopa 65 mg capsule; Carbidopa and levodopa 25mg/100mg; Carbidopa fu; Carbidopa levodopa; Carbidopa monohydrate; Carbidopa, levodopa, entacapone; Carbidopa- levodopa; Carbidopa-levodopa; Carbidopa/l-dopa; Carbidopa/l-dopa/entacapone; Carbidopa/levodopa; Carbidopa/levodopa, immediate release; Carbidopa/levodopa/entacapone; Comparator: carbidopa; Continuous intrajejunal infusion of levodopa-carbidopa; Controlled-release levodopa / carbidopa; Entacapone and carbidopa; Immediate release carbidopa/levodopa; Immediate release carbidopa/levodopa 25/100 mg; Levodopa and carbidopa; Levodopa and carbidopa sc solution; Levodopa and carbidopa solution for sc administration; Levodopa carbidopa (lc) oral encapsulated immediate release (ir) tablets; Levodopa carbidopa intestinal gel (lcig); Levodopa, carbidopa, entacapone; Levodopa, carbidopa, odm-104; Levodopa-carbidopa; Levodopa-carbidopa (lc) oral encapsulated immediate release (ir) tablets; Levodopa-carbidopa immediate release (lc-ir) tablets; Levodopa-carbidopa intestinal gel; Levodopa-carbidopa multilayer extended release tablet; Levodopa-carbidopa xl tablet (m); Levodopa-carbidopa-entacapone; Levodopa/carbidopa; Levodopa/carbidopa (4:1); Levodopa/carbidopa (sinemet); Levodopa/carbidopa 100/25; Levodopa/carbidopa hydrate; Levodopa/carbidopa solution; Levodopa/carbidopa(200mg/50mg); Levodopa/carbidopa/entacapone; Nd0612 (levodopa/carbidopa solution); Odm-101 105mg carbidopa; Odm-101 65mg carbidopa; Oral levodopa and carbidopa; Oral levodopa/carbidopa; Sinemet (levodopa/carbidopa); Sinemet plus (levodopa/carbidopa); Sinemet® controlled release (carbidopa/levodopa); Stalevo (levodopa/ carbidopa/ entacapone); Stalevo (levodopa/carbidopa/entacapona); Xp21279 and carbidopa (experimental); | D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
8件: 2, 4, 6, 13, 17, 90, 164, 201 |
38 | Carnosine | 3件: Carnosine; Carnosine supplementation; Carnosine, capsulle, 2 g/day, 8 weeks; | - |
- |
- |
2件: 6, 13 |
39 | Carvedilol | 2件: Carvedilol; Spironolactone captopril carvedilol; | D00255 D03415 |
5件: ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2 |
12件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
4件: 6, 57, 86, 113 |
40 | Ceftriaxone | 1件: Ceftriaxone; | D00924 D07659 |
- |
- |
3件: 2, 6, 97 |
41 | Chloride ion | - | - |
- |
- |
17件: 6, 11, 13, 14, 34, 46, 51, 96, 97, 127, 168, 193, 227, 228, 288, 297, 299 |
42 | Chloroxylenol | - | D03473 |
- |
- |
4件: 6, 13, 46, 168 |
43 | Cholecalciferol | 9件: 5000 iu of cholecalciferol; Calcium and cholecalciferol; Cholecalciferol; Cholecalciferol (vitamin d3); Cholecalciferol 10,000 iu; Cholecalciferol 400 iu; Cholecalciferol and c. xanthorrhiza; Cholecalciferol concentrate; Cholecalciferol, vitamin d3; | D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
15件: 6, 13, 19, 20, 34, 46, 49, 53, 60, 65, 96, 97, 228, 298, 299 |
44 | Clarithromycin | 6件: Biaxin ( clarithromycin); Clarithromycin; Lansoprazole, amoxicillin, clarithromycin; Lansoprazole, clarithromycin, amoxycillin; Rifabutin, clarithromycin, and clofazimine; Takecab tablets + amoxicillin + clarithromycin (first-line eradication) takecab tablets + amoxicillin + metronidazole (second-line eradication); | D00276 |
- |
- |
8件: 6, 63, 84, 96, 97, 222, 228, 299 |
45 | Clonazepam | 1件: Clonazepam; | D00280 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 6 |
46 | Clonidine | 3件: Clonidine; Clonidine hcl cf 0,150 mg, tabletten; Clonidine hydrochloride; | D00281 D00604 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
2件: 6, 78 |
47 | Clozapine | 1件: Clozapine; | D00283 |
11件: ADRA2A, ADRA2B, ADRA2C, DRD4, HTR2A, HTR2C, HTR3A, HTR3B, HTR3C, HTR3D, HTR3E |
8件: Calcium signaling pathway, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction, cGMP-PKG signaling pathway |
1件: 6 |
48 | Cobalt chloride | - | - |
- |
- |
1件: 6 |
49 | Cocoa | 3件: Cocoa; Dark chocolate (85% cocoa); White chocolate (0% cocoa); | - |
- |
- |
1件: 6 |
50 | Creatine | 4件: Creatine; Creatine monohydrate; Creatine-13c; Pyruvate, creatine, niacinamide; | - |
- |
- |
12件: 1, 2, 5, 6, 8, 13, 46, 49, 50, 113, 156, 201 |
51 | Cyanocobalamin | - | D00166 D03615 D03616 D03617 |
- |
- |
12件: 6, 13, 49, 62, 86, 96, 97, 201, 229, 254, 284, 299 |
52 | D-Serine | 2件: D-serine; D-serine (~2g/day); | - |
- |
- |
1件: 6 |
53 | D-glucose | 3件: 2-deoxy-2 [f-18] fluoro-2-d-glucose; [18f]fluoro-2-deoxy-2-d-glucose; D-glucose; | D00009 |
- |
- |
6件: 6, 13, 49, 86, 88, 299 |
54 | Darifenacin | 2件: Darifenacin; Oxybutynin and darifenacin; | D01699 D03654 |
1件: CHRM3 |
9件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction |
2件: 6, 13 |
55 | Date | 1件: Date; | - |
- |
- |
3件: 6, 88, 113 |
56 | Deanol | 2件: Deanol; Deanol pyroglutamate; | D07777 |
- |
- |
1件: 6 |
57 | Deferiprone | 7件: Deferiprone; Deferiprone (ferriprox); Deferiprone 600 mg delayed release tablet; Deferiprone 80 mg/ml oral solution; Deferiprone 80 mg/ml oral solution (ferriprox); Deferiprone oral solution; Ferrprox (deferiprone); | D07416 |
- |
- |
5件: 2, 6, 120, 122, 233 |
58 | Desmopressin | 7件: Ddavp (desmopressin); Desmopressin; Desmopressin acetat; Desmopressin acetate; Desmopressin acetate trihydrate; Desmopressin intranasal; Desmopressin oral melt; | D00291 D02235 |
2件: AVPR2, F8 |
4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
6件: 6, 64, 72, 75, 225, 288 |
59 | Dexmedetomidine | 8件: Dexmedetomidine; Dexmedetomidine 1; Dexmedetomidine 2; Dexmedetomidine 3; Dexmedetomidine and fentanyl; Dexmedetomidine group; Dexmedetomidine hydrochloride; Dexmedetomidine hydrochloride infusion; | D00514 D01205 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
11件: 2, 4, 6, 21, 34, 70, 113, 212, 215, 226, 280 |
60 | Dextromethorphan | 9件: Dextromethorphan; Dextromethorphan 30 mg; Dextromethorphan and caffeine; Dextromethorphan hbr and quinidine sulfate; Dextromethorphan hydrobromide; Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg; Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg; Dextromethorphan/quinidine 20mg/10mg (dm/q 20mg/10mg); Dimebon + dextromethorphan; | D00848 D03742 D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
9件: 2, 6, 8, 13, 46, 78, 96, 97, 156 |
61 | Dihydrotachysterol | - | D00299 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 6 |
62 | Dipivefrin | 1件: Dipivefrin; | D02349 |
9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
63 | Dipraglurant | 1件: Dipraglurant; | - |
- |
- |
1件: 6 |
64 | Doconexent | - | - |
- |
- |
7件: 6, 49, 90, 94, 240, 299, 301 |
65 | Domperidone | 3件: Domperidone; Domperidone (drug); Levodopa and domperidone; | D01745 D07868 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
5件: 6, 13, 17, 51, 230 |
66 | Donepezil | 4件: Donepezil; Donepezil hci (drug); Donepezil hydrochloride; Donepezil sandoz; | D00670 D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
9件: 5, 6, 13, 46, 78, 124, 127, 156, 206 |
67 | Dopamine | 9件: Bromocriptine and other dopamine agonists; Cerebral dopamine neurotrophic factor; Continuous release dopamine agonists; Dopamine; Dopamine agent; Dopamine agonist treatment; Dopamine agonists; Dopamine agonists (pramipexole, ropirinole); Recombinant human cerebral dopamine neurotrophic factor; | D00633 D07870 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
3件: 6, 7, 74 |
68 | Doxepin | 2件: Doxepin; Doxepin and zopiclone; | D00814 D07875 |
3件: HRH1, SLC6A2, SLC6A4 |
5件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle |
1件: 6 |
69 | Droxidopa | 1件: Droxidopa; | D01277 |
9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
3件: 5, 6, 17 |
70 | Duloxetine | 3件: Duloxetine; Duloxetine hydrochloride; Duloxetine hydrochloride (hci); | D01179 D07880 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 6, 13, 49 |
71 | Eliprodil | 1件: Eliprodil; | - |
- |
- |
1件: 6 |
72 | Eltoprazine | 3件: Eltoprazine; Eltoprazine hcl; Eltoprazine hydrochloride; | - |
- |
- |
1件: 6 |
73 | Entacapone | 12件: Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg); Carbidopa, levodopa, entacapone; Carbidopa/l-dopa/entacapone; Carbidopa/levodopa/entacapone; Entacapone; Entacapone and carbidopa; Levodopa, carbidopa, entacapone; Levodopa-carbidopa-entacapone; Levodopa/carbidopa/entacapone; Over-encapsulated entacapone tablets; Stalevo (levodopa/ carbidopa/ entacapone); V1512 and entacapone; | D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
2件: 6, 17 |
74 | Epigallocatechin gallate | 2件: Coconut oil and epigallocatechin gallate; Epigallocatechin gallate; | - |
- |
- |
8件: 6, 13, 17, 28, 85, 113, 206, 299 |
75 | Epinephrine | 4件: Bupivacaine/epinephrine/dexamethasone; Epinephrine; Lap tap bupivacaine/epinephrine; Us tap bupivacaine/epinephrine; | D00095 D00996 D02149 |
9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
9件: 6, 13, 46, 86, 96, 168, 226, 231, 256 |
76 | Ergoloid mesylate | - | D02268 |
6件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C |
7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 6 |
77 | Erythromycin | 2件: Erythromycin; Oral erythromycin; | D00140 D00851 D01361 D02009 D02184 D02523 D02524 D02525 D04054 |
- |
- |
5件: 6, 36, 164, 228, 291 |
78 | Erythropoietin | 4件: Erythropoietin; Erythropoietin human recombinant (eporh); Recombinant human erythropoietin; Recombinant human erythropoietin(rhepo); | D03231 |
1件: EPOR |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
9件: 2, 6, 13, 22, 46, 47, 70, 95, 96 |
79 | Escitalopram | 3件: Escitalopram; Escitalopram oxalate antidepressant; Oral escitalopram; | D02567 D07704 D07913 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 2, 6, 13 |
80 | Esomeprazole | 3件: Esomeprazole; Esomeprazole 20 mg; Nexium (esomeprazole magnesium); | D01984 D04056 D07917 D09339 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
6件: 6, 46, 86, 98, 298, 299 |
81 | Eszopiclone | 1件: Eszopiclone; | D02624 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
3件: 6, 13, 46 |
82 | Exametazime | 2件: Exametazime; Technetium (99mtc) exametazime; | D01109 |
- |
- |
1件: 6 |
83 | Exenatide | 3件: Exenatide; Exenatide 10 micrograms; Exenatide 5 micrograms; | D04121 |
1件: GLP1R |
3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
3件: 6, 193, 233 |
84 | Famotidine | 2件: Famotidine; Famotidine 20 mg; | D00318 |
1件: HRH2 |
3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction |
3件: 6, 46, 86 |
85 | Febuxostat | 1件: Febuxostat; | D01206 |
1件: XDH |
5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
3件: 2, 6, 13 |
86 | Fesoterodine | 1件: Fesoterodine; | D07226 |
2件: CHRM2, CHRM3 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 6 |
87 | Filgrastim | 6件: Ep2006 (filgrastim); Filgrastim; Filgrastim (g-csf); Filgrastim hexal; Filgrastim, alemtuzumab; Granulocyte colony-stimulating factor (filgrastim); | D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
28件: 2, 6, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 85, 96, 113, 164, 283, 284, 285, 331 |
88 | Finasteride | 1件: Finasteride; | D00321 |
1件: SRD5A2 |
2件: Prostate cancer, Steroid hormone biosynthesis |
1件: 6 |
89 | Fipamezole | 7件: Fipamezole; Fipamezole hydrochloride; Fipamezole hydrochloride 30 mg oral disintegrating tablets; Fipamezole hydrochloride 60 mg oral disintegrating tablets; Fipamezole hydrochloride 90 mg oral disintegrating tablets; Fipamezole odt; Fipamezole odt cohort 2; | - |
- |
- |
2件: 6, 17 |
90 | Flecainide | 2件: Flecainide; Flecainide acetate; | D00638 D07962 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
1件: 6 |
91 | Florbenazine F-18 | - | - |
- |
- |
1件: 6 |
92 | Fludeoxyglucose F-18 | 1件: Fludeoxyglucose f 18; | - |
- |
- |
8件: 6, 13, 34, 46, 53, 84, 127, 300 |
93 | Fludrocortisone | 1件: Fludrocortisone; | D00986 D07967 |
1件: NR3C2 |
1件: Aldosterone-regulated sodium reabsorption |
3件: 6, 17, 81 |
94 | Flumazenil | 4件: 11c-flumazenil; [11c]flumazenil; Flumazenil; Pet with 11c-flumazenil; | D00697 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
5件: 6, 13, 17, 18, 206 |
95 | Flutemetamol | 2件: Flutemetamol; Vizamyl (flutemetamol(f-18)); | - |
- |
- |
5件: 5, 6, 7, 17, 127 |
96 | Folic acid | 5件: Folic acid; Folic acid or folate; Folic acid, vitamin b6, vitamin b12; Methotrexate and folic acid; Rituximab, mtx, folic acid; | D00070 |
- |
- |
11件: 6, 13, 46, 49, 62, 84, 86, 96, 97, 254, 284 |
97 | Foliglurax | 1件: Foliglurax; | - |
- |
- |
1件: 6 |
98 | Fursultiamine | 1件: Fursultiamine; | D03319 |
- |
- |
1件: 6 |
99 | GPI-1485 | 1件: Gpi 1485; | - |
- |
- |
1件: 6 |
100 | Gabapentin | 3件: Gabapentin; Gabapentin prescriptions; Transdermal fentanyl matrix, gabapentin; | D00332 |
5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 |
9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), GABAergic synapse, Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
7件: 6, 13, 19, 70, 97, 226, 298 |
101 | Galantamine | 2件: Galantamine; Galantamine hydrobromide; | D02173 D04292 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
2件: 6, 127 |
102 | Ginkgo biloba | 2件: Ginkgo biloba; Ginkgo biloba pills sig: 300mg/tid; | - |
- |
- |
3件: 6, 13, 90 |
103 | Glutathione | 10件: Glutathione; Glutathione sodium; Gsh (glutathione); Inhaled reduced glutathione; Intranasal glutathione - (in)gsh; Oral glutathione; Oral reduced l-glutathione; Reduced glutathione; Reduced glutathione 100mg; Reduced glutathione 200mg; | D00014 D00031 |
- |
- |
2件: 6, 299 |
104 | Glycerin | - | D00028 |
- |
- |
6件: 6, 13, 53, 265, 316, 317 |
105 | Glycerol phenylbutyrate | 1件: Glycerol phenylbutyrate; | D10127 |
- |
- |
2件: 6, 251 |
106 | Glycopyrronium | - | D00540 D10938 |
1件: CHRM3 |
9件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction |
1件: 6 |
107 | Gold | 3件: Gold; Gold nanocrystals; Sodium aurothiomalate (intramuscular gold); | - |
- |
- |
5件: 2, 6, 13, 46, 171 |
108 | Grapefruit | 2件: Grapefruit; Grapefruit juice; | - |
- |
- |
5件: 6, 46, 50, 83, 97 |
109 | Green tea leaf | 1件: Green tea leaf; | D06903 |
- |
- |
5件: 6, 17, 28, 46, 96 |
110 | Heptaminol | 2件: Heptaminol; Heptaminol hydrochloride; | D07158 |
- |
- |
1件: 6 |
111 | Hydrocortisone | 22件: Combination oral budesonide and rectal hydrocortisone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cortef (hydrocortisone); Dual release hydrocortisone (plenadren); Hydrocortisone; Hydrocortisone (solucortef); Hydrocortisone 10mg tablet; Hydrocortisone 20mg tablets; Hydrocortisone cream; Hydrocortisone cream 1%; Hydrocortisone cream 10mg/g fna fagron; Hydrocortisone efcortesol & solu-cortef; Hydrocortisone modified release capsules; Hydrocortisone roussel; Hydrocortisone sodium acetate; Hydrocortisone sodium phosphate; Hydrocortisone sodium succinate; Hydrocortisone takeda, tabletter; Mesalazine with hydrocortisone sodium succinate; Solu-cortef (hydrocortisone); Subcutaneous hydrocortisone; Subcutaneous hydrocortisone 10mg; | D00088 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
8件: 6, 53, 75, 78, 81, 83, 97, 299 |
112 | Hydrocortisone acetate | - | D00165 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
8件: 6, 53, 75, 78, 81, 83, 97, 299 |
113 | Hydrocortisone succinate | - | D01442 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
3件: 6, 81, 83 |
114 | Hydrogen | 2件: Hydrogen; Tch346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt); | - |
- |
- |
5件: 5, 6, 17, 97, 226 |
115 | ITI-214 | 1件: Iti-214; | - |
- |
- |
1件: 6 |
116 | Idebenone | 2件: Idebenone; Idebenone 150 mg film-coated tablets; | D01750 |
- |
- |
4件: 6, 13, 113, 302 |
117 | Inosine | 2件: 1) inosine 5'-monophosphate; Inosine; | D00054 |
- |
- |
4件: 2, 6, 13, 17 |
118 | Iodide I-123 | - | - |
- |
- |
2件: 2, 6 |
119 | Ioflupane I-123 | 1件: Ioflupane i 123; | D10014 |
- |
- |
3件: 2, 5, 6 |
120 | Ipratropium | 4件: Ipratropium; Ipratropium bromide (drug); Nebulized combination ipratropium bromide with salbutamol; Nebulized ipratropium bromide; | D02212 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
2件: 6, 86 |
121 | Iproniazid | 1件: Iproniazid; | D02579 |
2件: MAOA, MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
122 | Isoflurane | 1件: Isoflurane; | D00545 |
- |
- |
1件: 6 |
123 | Isoxaflutole | - | - |
- |
- |
8件: 5, 6, 13, 18, 81, 113, 149, 299 |
124 | Isradipine | 5件: Dynacirc cr (isradipine); Isradipine; Isradipine cr 10mg; Isradipine cr 20mg; Isradipine cr 5mg; | D00349 |
4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S |
34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
125 | Istradefylline | 8件: Istradefylline; Istradefylline ( kw-6002); Istradefylline (kw-6002); Istradefylline 20 mg; Istradefylline 20 mg or 40 mg; Istradefylline 40 mg; Kw-6002 (istradefylline); Rifampin 300mg bid + istradefylline 40mg day 8 only; | D04641 |
1件: ADORA2A |
7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
1件: 6 |
126 | Ketamine | 3件: Ketamine; S-ketamine; S-ketamine & midazolam; | D00711 D08098 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
6件: 6, 13, 70, 113, 156, 215 |
127 | L-Cysteine | - | D00026 D02326 |
- |
- |
9件: 6, 13, 19, 84, 85, 88, 90, 254, 296 |
128 | L-Leucine | 1件: L-leucine; | D00030 |
- |
- |
7件: 5, 6, 7, 127, 283, 284, 299 |
129 | L-Tryptophan | - | D00020 |
- |
- |
1件: 6 |
130 | Lactobacillus plantarum | 3件: Lactobacillus plantarum; Lactobacillus plantarum ps128; Probiotic-lactobacillus plantarum ps128; | - |
- |
- |
2件: 6, 156 |
131 | Lactose | 3件: Lactose; Lactose in water; Lactose monohydrate; | D00046 D03226 |
- |
- |
6件: 2, 6, 13, 97, 228, 310 |
132 | Lenomorelin | - | - |
- |
- |
3件: 6, 78, 299 |
133 | Leptin | 3件: Hu leptin (a-100); Human recombinant leptin (metreleptin); Leptin; | - |
- |
- |
2件: 6, 265 |
134 | Levetiracetam | 1件: Levetiracetam; | D00709 |
1件: SV2A |
1件: ECM-receptor interaction |
4件: 2, 4, 6, 13 |
135 | Levodopa | 87件: Accordion pill carbidopa/levodopa; Accordion pill™ carbidopa/levodopa; Accordion pill™ carbidopa/levodopa 50/400 mg; Accordion pill™ carbidopa/levodopa 50/500 mg; Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg); Carbidopa and levodopa 25mg/100mg; Carbidopa levodopa; Carbidopa, levodopa, entacapone; Carbidopa- levodopa; Carbidopa-levodopa; Carbidopa/levodopa; Carbidopa/levodopa, immediate release; Carbidopa/levodopa/entacapone; Comparator: levodopa; Continuous intrajejunal infusion of levodopa-carbidopa; Controlled-release levodopa / carbidopa; Immediate release carbidopa/levodopa; Immediate release carbidopa/levodopa 25/100 mg; Intravenous levodopa; Iv levodopa; Levodopa; Levodopa (delivered intravenously); Levodopa (drug), intraduodenal administration; Levodopa (l-dopa); Levodopa (l-dopa) + standard care; Levodopa / benserazid; Levodopa / benserazide 200 + 50 mg; Levodopa 100 mg / benserazide 25 mg; Levodopa 100 mg a cap; Levodopa 125 mg a cap; Levodopa 150 mg a cap; Levodopa 25mg/100mg; Levodopa 75 mg a cap; Levodopa acute challenge; Levodopa and carbidopa; Levodopa and carbidopa sc solution; Levodopa and carbidopa solution for sc administration; Levodopa and decarboxylase inhibitor; Levodopa and domperidone; Levodopa benserazide madopar; Levodopa benserazide teva italia; Levodopa carbidopa (lc) oral encapsulated immediate release (ir) tablets; Levodopa carbidopa intestinal gel (lcig); Levodopa cr (controlled release); Levodopa cyclops; Levodopa dc.it fu; Levodopa dispersible; Levodopa infusion; Levodopa mr; Levodopa powder for inhalation; Levodopa test; Levodopa, carbidopa, entacapone; Levodopa, carbidopa, odm-104; Levodopa, decarboxylase inhibitor and comt inhibitor; Levodopa-carbidopa; Levodopa-carbidopa (lc) oral encapsulated immediate release (ir) tablets; Levodopa-carbidopa immediate release (lc-ir) tablets; Levodopa-carbidopa intestinal gel; Levodopa-carbidopa multilayer extended release tablet; Levodopa-carbidopa xl tablet (m); Levodopa-carbidopa-entacapone; Levodopa/benserazide; Levodopa/benserazide 100/25 mg; Levodopa/benzeraside; Levodopa/benzerazide; Levodopa/carbidopa; Levodopa/carbidopa (4:1); Levodopa/carbidopa (sinemet); Levodopa/carbidopa 100/25; Levodopa/carbidopa hydrate; Levodopa/carbidopa solution; Levodopa/carbidopa(200mg/50mg); Levodopa/carbidopa/entacapone; Levodopa/ddci; Nacom levodopa+cardidopa; Nd0612 (levodopa/carbidopa solution); Oral levodopa and carbidopa; Oral levodopa/carbidopa; Rasagiline mesylate with levodopa; Safinamide + levodopa; Sinemet (levodopa/carbidopa); Sinemet plus (levodopa/carbidopa); Sinemet® controlled release (carbidopa/levodopa); Stalevo (levodopa/ carbidopa/ entacapone); Stalevo (levodopa/carbidopa/entacapona); Tvp-1012 (1 mg/day) with levodopa; Tvp-1012 1mg with levodopa; | D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
7件: 2, 4, 6, 17, 90, 164, 201 |
136 | Levomefolic acid | - | D09353 |
- |
- |
1件: 6 |
137 | Liatermin | 2件: Liatermin; Liatermin (r-methugdnf); | D04727 |
- |
- |
1件: 6 |
138 | Lidocaine | 8件: 5% lidocaine/5 mg/ml estradiol compound cream; Alkalinized lidocaine-heparin; Bladder instillation with heparin/ lidocaine; Lidocaine; Lidocaine injection 2%; Lidocaine patch 5%; Lidocaine releasing intravesical system - liris®; Local anesthesia (lidocaine hydrochloride); | D00358 D02086 D08127 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
10件: 6, 13, 46, 84, 86, 97, 168, 226, 231, 256 |
139 | Liraglutide | 1件: Liraglutide; | D06404 |
1件: GLP1R |
3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
3件: 6, 75, 193 |
140 | Lisuride | 5件: Lisuride; Lisuride hydrogenmaleate; Lisuride transdermal system; Lisuride tts 10cm²; Lisuride tts 20cm²; | D01462 D08132 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
2件: 6, 86 |
141 | Lixisenatide | 1件: Lixisenatide; | D09729 |
1件: GLP1R |
3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 6 |
142 | Loratadine | 1件: Loratadine; | D00364 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
3件: 6, 13, 46 |
143 | Lovastatin | 5件: Lovastatin; Lovastatin 60 mg; Lovastatin ™; Lovastatin, then minocycline/lovastatin; Minocycline, then minocycline/lovastatin; | D00359 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
10件: 6, 34, 46, 79, 156, 160, 195, 206, 263, 310 |
144 | Lubiprostone | 1件: Lubiprostone; | D04790 |
1件: CLCN2 |
1件: Mineral absorption |
4件: 6, 13, 290, 299 |
145 | Magnesium | 16件: (s)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide; (s)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide; Magnesium; Magnesium citrate; Magnesium gluconate; Magnesium hydroxide; Magnesium oxide; Magnesium sulfate; Mineral boost (magnesium); Nexium (esomeprazole magnesium); Omeprazole magnesium; Saroglitazar magnesium 2 mg; Saroglitazar magnesium 4 mg; Sodium picosulfate, magnesium oxide and citric acid; Sodium picosulfate/magnesium citrate laxative; Sulfate, magnesium; | - |
- |
- |
15件: 6, 11, 13, 46, 64, 93, 97, 166, 225, 235, 284, 291, 296, 297, 298 |
146 | Magnesium oxide | 2件: Magnesium oxide; Sodium picosulfate, magnesium oxide and citric acid; | D01167 |
- |
- |
3件: 6, 166, 291 |
147 | Maltodextrin | 3件: Maltodextrin; Maltodextrin fiber supplement; Resistant maltodextrin; | D02329 |
- |
- |
4件: 6, 13, 96, 97 |
148 | Mannitol | 7件: Dp mannitol; Idpm: inhaled dry powder mannitol; Inhaled dry powder mannitol; Inhaled mannitol; Mannitol; Mannitol + pulmozyme; Mannitol inhalation powder; | D00062 |
- |
- |
3件: 6, 96, 299 |
149 | Masitinib | 10件: Masitinib; Masitinib (3.0); Masitinib (4.5); Masitinib (6.0); Masitinib (ab1010); Masitinib 100mg; Masitinib 200mg; Masitinib 3 mg; Masitinib 6.0 mg; Masitinib mesylate; | D10229 |
1件: KIT |
11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
6件: 2, 5, 6, 13, 46, 96 |
150 | Medical Cannabis | - | - |
- |
- |
6件: 2, 6, 13, 90, 96, 97 |
151 | Melatonin | 10件: 3 mg melatonin; 5 mg melatonin; Circadin ( inn= melatonin); Diazepam, melatonin; Dtr melatonin (nih cc pds); Hourly dosing of the nychtemeral secretion of melatonin; Melatonin; Melatonin cr; Melatonin pr; Melatonin(circadin®); | D08170 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
8件: 6, 13, 46, 49, 90, 97, 144, 202 |
152 | Melevodopa | 2件: Melevodopa; Melevodopa and decarboxylase inhibitor; | D07304 |
- |
- |
1件: 6 |
153 | Melperone | 2件: Melperone; Melperone hcl; | D07309 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
154 | Memantine | 3件: Memantine; Memantine (ebixa); Memantine hydrochloride; | D04905 D08174 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
7件: 2, 6, 8, 13, 49, 127, 205 |
155 | Metformin | 12件: 750 mg metformin and 7.5 g l-citrulline daily p.o.; Glucophage (metformin); L-citrulline and metformin & l-citrulline; Metformin; Metformin (generic); Metformin 500mg; Metformin and metformin & l-citrulline; Metformin hcl; Metformin hydrochloride; Metformin/cp-690,550; Pioglitazone or metformin; Sitagliptin and metformin; | D00944 D04966 |
2件: PRKAA1, PRKAA2 |
19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
17件: 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
156 | Methylphenidate | 11件: D-methylphenidate; Methylphenidate; Methylphenidate (mpd); Methylphenidate (overencapsulated); Methylphenidate 10mg tablets; Methylphenidate hydrochloride; Methylphenidate modified release; Methylphenidate modified release 20 mg; Methylphenidate modified release 30 mg; Methylphenidate modified release 40 mg; Methylphenidate, fluoxetin, risperidone; | D01296 D04999 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
7件: 6, 13, 34, 84, 113, 179, 206 |
157 | Midazolam | 6件: Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Midazolam; Midazolam 2 mg; Midazolam 3 mg; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; S-ketamine & midazolam; | D00550 D00696 D05028 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
10件: 2, 3, 6, 13, 46, 70, 96, 97, 231, 298 |
158 | Midodrine | 2件: Midodrine; Midodrine hydrochloride; | D01307 D08220 |
3件: ADRA1A, ADRA1B, ADRA1D |
7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
3件: 6, 17, 58 |
159 | Minocycline | 7件: Combination of minocycline and mtx or mtx alone; Glatiramer acetate with minocycline; Lovastatin, then minocycline/lovastatin; Minocycline; Minocycline 100 mg film-coated tablets; Minocycline hydrochloride; Minocycline, then minocycline/lovastatin; | D00850 D05045 |
- |
- |
14件: 2, 6, 8, 13, 46, 84, 85, 90, 94, 162, 201, 206, 280, 299 |
160 | Minodronic acid | 1件: Minodronic acid; | - |
- |
- |
4件: 6, 46, 93, 95 |
161 | Mirabegron | 1件: Mirabegron; | D09535 |
1件: ADRB3 |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cGMP-PKG signaling pathway |
3件: 6, 13, 226 |
162 | Moclobemide | 1件: Moclobemide; | D02561 |
1件: MAOA |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
163 | Modafinil | 4件: Modafinil; Modafinil 50mg; Over-encapsulated modafinil; Provigil (modafinil); | D01832 |
- |
- |
4件: 6, 13, 49, 93 |
164 | Moxifloxacin | 5件: Avelox- moxifloxacin; Moxifloxacin; Moxifloxacin 400 mg; Moxifloxacin hydrochloride; Moxifloxacin infusion; | D00874 D08237 |
- |
- |
8件: 2, 6, 46, 49, 85, 86, 240, 299 |
165 | Muscimol | 1件: Muscimol; | - |
- |
- |
1件: 6 |
166 | Nabilone | 3件: Cesamet™ (nabilone); Nabilone; Nabilone 0.25 mg; | D05099 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
2件: 6, 13 |
167 | Nalmefene | 1件: Nalmefene; | D05111 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
168 | Naloxone | 8件: Naloxone; Naloxone hydrochloride; Oxycodone naloxone prolonged release tablets; Oxycodone/naloxone prolonged release t; Oxycodone/naloxone prolonged release tablets; Oxycodone/naloxone prolonged release tablets 10/5 mg; Oxycodone/naloxone prolonged release tablets 20/10 mg; Oxycodone/naloxone prolonged release tablets 5/2.5 mg; | D01340 D08249 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
2件: 6, 226 |
169 | Naltrexone | 5件: 4.5 mg naltrexone; Low dose naltrexone; Naltrexone; Naltrexone hydrochloride; Naltrexone-hcl; | D02095 D05113 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
170 | Nebicapone | 1件: Nebicapone; | - |
- |
- |
1件: 6 |
171 | Nelotanserin | 1件: Nelotanserin; | D09645 |
1件: HTR2A |
5件: Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse |
1件: 6 |
172 | Neridronic Acid | 1件: Neridronic acid; | - |
- |
- |
1件: 6 |
173 | Niacin | 5件: Dose-establishing study 1 niacin 250mg; Dose-establishing study 1 niacin 500mg; Dose-establishing study 2 niacin 500mg; Niacin; Niacin first; | D00049 |
- |
- |
4件: 6, 78, 79, 265 |
174 | Nicotinamide | 2件: Nicotinamide; Nicotinamide riboside; | D00036 |
- |
- |
8件: 5, 6, 13, 46, 49, 53, 67, 162 |
175 | Nicotinamide riboside | 1件: Nicotinamide riboside; | - |
- |
- |
1件: 6 |
176 | Nicotine | 6件: Nicotine; Nicotine gum; Nicotine nasal spray 10 mg/ml (0.5 mg/spray); Nicotine patch; Nicotine transdermal patch; Transdermal nicotine; | D03365 D05156 D05157 |
16件: CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG |
5件: Calcium signaling pathway, Chemical carcinogenesis, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction |
2件: 6, 84 |
177 | Nilotinib | 8件: Cohort 1:nilotinib oral capsules (150mg or 300mg); Cohort 2: nilotinib oral capsules (dose to be determined from cohort 1); Nilotinib; Nilotinib (tasigna); Nilotinib 150 mg; Nilotinib 150mg oral capsule [tasigna]; Nilotinib 300mg oral capsule [tasigna]; Nilotinib hydrochloride monohydrate; | D08953 |
4件: ABL1, KIT, PDGFRA, PDGFRB |
33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
5件: 6, 8, 34, 51, 86 |
178 | Nitrogen | 1件: Nitrogen; | D00083 |
- |
- |
5件: 5, 6, 17, 211, 299 |
179 | Nortriptyline | 1件: Nortriptyline; | D00816 D08288 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
2件: 6, 226 |
180 | Omeprazole | 16件: Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Clartihromycin, amoxicillin, and omeprazole; Diclofenac + omeprazole; Dimebon + omeprazole; Naproxen 500 mg tablets (pn 200 minus omeprazole); Omeprazole; Omeprazole (uk licensed generic product); Omeprazole 20 mg; Omeprazole 20mg; Omeprazole 20mg bid; Omeprazole 40 mg; Omeprazole 40mg capsule; Omeprazole magnesium; Omeprazole rectally 1mg/kg; Pn 200 tablets (500 mg naproxen and 20 mg omeprazole); Rifaximin+omeprazole+miralax; | D00455 D01207 D05259 D05261 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
15件: 6, 8, 13, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
181 | Opicapone | 2件: Opicapone; Opicapone (opc); | D10825 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
182 | Oxybuprocaine | 1件: Oxybuprocaine; | D01768 D08319 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
1件: 6 |
183 | Oxybutynin | 3件: Oxybutynin; Oxybutynin and darifenacin; Oxybutynin hydrochloride; | D00465 D00722 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 6 |
184 | Oxycodone | 14件: Extended-release oxycodone; Oxycodone; Oxycodone by patient-controlled analgesia (pca); Oxycodone depot ”sandoz”, depot tablets; Oxycodone hydrochloride; Oxycodone naloxone prolonged release tablets; Oxycodone orion; Oxycodone/acetaminophen; Oxycodone/naloxone prolonged release t; Oxycodone/naloxone prolonged release tablets; Oxycodone/naloxone prolonged release tablets 10/5 mg; Oxycodone/naloxone prolonged release tablets 20/10 mg; Oxycodone/naloxone prolonged release tablets 5/2.5 mg; Pr oxycodone; | D03783 D05312 D05462 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
7件: 6, 13, 46, 70, 226, 231, 298 |
185 | Oxygen | 9件: Continuous oxygen; Helium / oxygen mixed gas inhalation therapy; Medical air vs oxygen; Medical grade oxygen; Nitric oxide plus oxygen; Oxygen; Oxygen 40 %; Oxygen supplementation; Perfluorinated gas/oxygen mixture; | D00003 |
- |
- |
18件: 5, 6, 17, 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 193, 211, 226, 299, 330 |
186 | Pardoprunox | 2件: Pardoprunox; Pardoprunox hydrochloride; | D09397 |
3件: DRD2, DRD3, HTR1A |
10件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
1件: 6 |
187 | Paroxetine | 3件: Paroxetine; Paroxetine & prednisolone; Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp; | D02260 D02362 D05374 D05375 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 6, 13, 46 |
188 | Perampanel | 3件: 2 mg perampanel; 4 mg perampanel; Perampanel; | D08964 |
4件: GRIA1, GRIA2, GRIA3, GRIA4 |
13件: Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Transcriptional misregulation in cancer, cAMP signaling pathway |
3件: 2, 6, 144 |
189 | Pergolide | 1件: Pergolide; | D00502 D08339 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
190 | Phenelzine | - | D00505 D08349 |
2件: MAOA, MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
191 | Phenylbutyric acid | - | D05868 |
- |
- |
10件: 2, 3, 6, 8, 93, 94, 244, 251, 297, 299 |
192 | Piclozotan | 1件: Piclozotan; | - |
- |
- |
1件: 6 |
193 | Pilocarpine | 2件: Pilocarpine; Pilocarpine nitrate 5%; | D00525 D02200 D05478 |
2件: CHRM2, CHRM3 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
3件: 6, 53, 299 |
194 | Pimavanserin | 5件: Active drug: pimavanserin 17mg (2 strength tablets); Pimavanserin; Pimavanserin (acp-103); Pimavanserin tartrate; Pimavanserin tartrate (acp-103); | - |
- |
- |
1件: 6 |
195 | Pioglitazone | 6件: Actos (pioglitazone); Pioglitazone; Pioglitazone 15 mg; Pioglitazone and tretinoin; Pioglitazone or metformin; Tretinoin and pioglitazone hcl; | D00945 D08378 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
196 | Piribedil | 2件: Piribedil; Piribedil (clarium); | D07305 |
2件: DRD2, DRD3 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
197 | Pitolisant | 2件: Bf2.649 (pitolisant); Pitolisant; | D10749 |
1件: HRH3 |
1件: Neuroactive ligand-receptor interaction |
1件: 6 |
198 | Pittsburgh Compound B | 2件: Pittsburgh compound b; Pittsburgh compound b (c-11 pib); | - |
- |
- |
2件: 6, 127 |
199 | Pramipexole | 20件: Dopamine agonists (pramipexole, ropirinole); Mirapex (pramipexole); P2b001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),; P2b001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),; Pramipexole; Pramipexole 0.125 mg tablets; Pramipexole 0.5 mg tablets; Pramipexole dihydrochloride; Pramipexole dihydrochloride extended-release tablets; Pramipexole dihydrochloride monohydrate; Pramipexole dihydrochloride monohydrate extended release; Pramipexole er; Pramipexole extended release; Pramipexole extended release tablet; Pramipexole immediate release; Pramipexole immediate release tablet; Pramipexole ir; Pramipexole or ropinirole; Pramipexole sr; R(+) pramipexole dihydrochloride monohydrate; | D00559 D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
2件: 2, 6 |
200 | Preladenant | 4件: Preladenant; Preladenant 10 mg tablet; Preladenant 2 mg tablet; Preladenant 5 mg tablet; | D09717 |
1件: ADORA2A |
7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
1件: 6 |
201 | Pridopidine | 2件: Pridopidine; Pridopidine (90 mg); | D09953 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
2件: 6, 8 |
202 | Propofol | 3件: Intubated with propofol (ip); Propofol; Propofol-lipuro; | D00549 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
8件: 6, 21, 22, 34, 46, 84, 98, 296 |
203 | Propranolol | 5件: Atenolol or propranolol; Losartan and atenolol or propranolol; Propranolol; Propranolol hcl cf 40 mg tablet; Propranolol treatment; | D00483 D08443 |
3件: ADRB1, ADRB2, ADRB3 |
11件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cAMP signaling pathway, cGMP-PKG signaling pathway |
5件: 6, 158, 167, 227, 278 |
204 | Pyridostigmine | 2件: Pyridostigmine; Pyridostigmine bromide; | D00487 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
4件: 3, 6, 11, 256 |
205 | Pyridoxine | 4件: Pyridoxine; Pyridoxine 10mg; Pyridoxine 10mg bp; Pyridoxine plus prednisolone; | D02179 D08454 |
- |
- |
4件: 6, 49, 93, 145 |
206 | Quetiapine | 2件: Extended-release quetiapine fumarate; Quetiapine; | D00458 D08456 |
2件: DRD2, HTR2A |
11件: Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, cAMP signaling pathway |
2件: 6, 13 |
207 | Raclopride | 2件: 11c-raclopride; Raclopride; | - |
- |
- |
4件: 5, 6, 7, 17 |
208 | Ramelteon | 1件: Ramelteon; | D02689 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
3件: 6, 8, 46 |
209 | Rasagiline | 16件: 1.0 mg rasagiline mesylate; Group r rasagiline; Group r+ad rasagiline + antidepressant; P2b001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),; P2b001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),; Rasagiline; Rasagiline 1 mg capsule; Rasagiline 1mg tablet; Rasagiline 2 mg tablet; Rasagiline mesilate; Rasagiline mesylate; Rasagiline mesylate 1.0 mg; Rasagiline mesylate plus mirapex; Rasagiline mesylate with levodopa; Rasagiline mesylate with requip; Rasagiline tablets; | D02562 D08469 D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
4件: 2, 5, 6, 17 |
210 | Remifentanil | 1件: Remifentanil; | D01177 D08473 |
1件: OPRM1 |
3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
2件: 6, 70 |
211 | Repaglinide | 2件: Repaglinide; Repaglinide and insulin; | D00594 |
2件: ABCC8, KCNJ11 |
4件: ABC transporters, GnRH secretion, Insulin secretion, Type II diabetes mellitus |
2件: 6, 299 |
212 | Reynoutria multiflora root | - | - |
- |
- |
1件: 6 |
213 | Rifampicin | 1件: Rifampicin; | D00211 |
- |
- |
7件: 6, 13, 17, 46, 84, 86, 299 |
214 | Rifaximin | 9件: Rifaximin; Rifaximin 550 mg; Rifaximin delayed release (dr); Rifaximin delayed release 400 mg film coated tablet; Rifaximin delayed release tablets; Rifaximin eir; Rifaximin oral tablet; Rifaximin+omeprazole+miralax; Rifaximin-eir; | D02554 |
- |
- |
7件: 6, 65, 94, 96, 97, 99, 296 |
215 | Rivastigmine | 5件: Exelon patch (rivastigmine transdermal system); Rivastigmine; Rivastigmine capsule; Rivastigmine patch 9.5 cm2; Rivastigmine transdermal patch; | D02558 D03822 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
3件: 5, 6, 13 |
216 | Ropinirole | 27件: Hp-3000 (ropinirole hydrochloride patch); Hp-3000(ropinirole hydrochloride patch); Pramipexole or ropinirole; Ropinirole; Ropinirole (as hydrochloride); Ropinirole controlled-release (requip cr) for rls; Ropinirole cr 2mg tablet; Ropinirole cr 8mg tablet; Ropinirole hydrochloride; Ropinirole hydrochloride extended-release tablet; Ropinirole hydrochloride extended-release tablet placebo; Ropinirole hydrochloride prolonged release; Ropinirole immediate release; Ropinirole implant; Ropinirole ir; Ropinirole ir tablets; Ropinirole monotherapy; Ropinirole oral product; Ropinirole pr; Ropinirole pr, 2mg; Ropinirole pr/xr; Ropinirole pr/xr tablets; Ropinirole prolonged release; Ropinirole prolonged release/extended release(pr/xr); Ropinirole xl; Ropinirole xl (formerly cr); Ropinirole/l-dopa; | D00784 D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
3件: 6, 74, 309 |
217 | Rosuvastatin | 6件: Calcium rosuvastatin; Crestor tablets (calcium rosuvastatin) film-coated tablets; Rosuvastatin; Rosuvastatin 10 mg; Rosuvastatin 20mg; Rosuvastatin calcium; | D01915 D08492 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
8件: 6, 46, 49, 51, 79, 96, 271, 299 |
218 | Rotigotine | 10件: Rotigotine; Rotigotine (reference product pr 2.1.1); Rotigotine (test product pr 2.3.1); Rotigotine hydrochloride; Rotigotine nasal spray; Rotigotine transdermal patch; Rotigotine transdermal patch 2mg/24h(10cm2); Rotigotine transdermal patch 4mg/24h (20cm2); Rotigotine transdermal patch 6mg/24h (30cm2); Rotigotine transdermal patch 8mg/24h (40cm2); | D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
219 | Safinamide | 9件: Safinamide; Safinamide + levodopa; Safinamide metansolfonato (12 weeks); Safinamide methanesulfonate; Safinamide methanesulfonate 100mg; Safinamide methanesulfonate 150mg; Safinamide methansulfonate; Safinamide, mao-b inhibitor; Xadago (safinamide); | D10158 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
2件: 6, 17 |
220 | Sage | 4件: Sage; Sage leaf; Sage-217; Sage-718; | - |
- |
- |
2件: 6, 8 |
221 | Saracatinib | 1件: Saracatinib; | D09664 |
2件: ABL1, SRC |
45件: Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection |
2件: 6, 89 |
222 | Sarcosine | 2件: Sarcosine; Sarcosine capsule; | - |
- |
- |
1件: 6 |
223 | Sargramostim | 3件: Gm-csf (granulocyte-macrophage colony-stimulating factor, sargramostim); Sargramostim; Sargramostim (leukine); | D05803 |
1件: CSF2RA |
4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
6件: 6, 28, 60, 62, 96, 229 |
224 | Sarizotan | 4件: Sarizotan; Sarizotan hc1; Sarizotan hcl; Sarizotan hydrochloride; | - |
- |
- |
2件: 6, 156 |
225 | Selegiline | 3件: Orally disintegrating selegiline (zelapar); Selegiline; Selegiline hcl 5 pch; | D00785 D03731 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
226 | Semaglutide | 1件: Semaglutide; | D10025 |
1件: GLP1R |
3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 6 |
227 | Serine | 4件: D-serine; D-serine (~2g/day); L-serine; Serine; | D00016 |
- |
- |
3件: 2, 6, 86 |
228 | Sertraline | 1件: Sertraline; | D00825 D02360 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 6, 8, 206 |
229 | Sevoflurane | 3件: Intubated with sevoflurane (is); Sevoflurane; Sevoflurane anesthetics; | D00547 |
- |
- |
5件: 6, 21, 22, 98, 296 |
230 | Sildenafil | 25件: 20 mg sildenafil citrate by mouth; 5% sildenafil cream; Access program - sildenafil citrate, viagra, revatio; Acute (1 hour) sildenafil; Bosentan and sildenafil; Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); Oral sildenafil; Sildenafil; Sildenafil (50 mg); Sildenafil (as citrate); Sildenafil (revatio); Sildenafil (revatio) 20 mg tid; Sildenafil 20 mg tablets; Sildenafil 20mg; Sildenafil 20mg and bosentan 62.5mg; Sildenafil 40mg oral capsule; Sildenafil and losartan; Sildenafil citrate; Sildenafil citrate (uk-92,480); Sildenafil singly or in association with bosentan; Sildenafil therapy; Sitaxsentan and sildenafil; Sodium tanshinone iia sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth; Sub-chronic (4 weeks) sildenafil; Tadalafil and sildenafil; | D02229 D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
16件: 6, 46, 50, 51, 85, 86, 96, 113, 210, 211, 212, 225, 226, 278, 294, 299 |
231 | Silodosin | 1件: Silodosin; | D01965 |
1件: ADRA1A |
7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
2件: 6, 13 |
232 | Simvastatin | 11件: Encapsulated simvastatin tablets; Ezetimibe+simvastatin drug combination; Simvastatin; Simvastatin 20mg/5ml oral suspension; Simvastatin 40 mg film-coated tablets; Simvastatin 40mg; Simvastatin alternova; Simvastatin susp.; Simvastatin treatment for 28 days; Simvastatin-ratiopharm; Simvastatin-ratiopharm®; | D00434 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
233 | Smilagenin | 1件: Smilagenin; | - |
- |
- |
1件: 6 |
234 | Sodium chloride | 14件: 0.9% sodium chloride; 0.9% sodium chloride (normal saline); 0.9% sodium chloride injection; 0.9% w/v sodium chloride solution; Isotonic sodium chloride solution; Physiological serum (sodium chloride); Sodium chloride; Sodium chloride (7%); Sodium chloride 0,9%; Sodium chloride 6%; Sodium chloride solution; Sodium chloride solution 0.9%; Sodium chloride solvent; Sodium pyruvate in 0.9% sodium chloride solution; | D02056 |
- |
- |
19件: 6, 11, 13, 14, 17, 34, 46, 51, 53, 67, 78, 86, 97, 168, 193, 227, 228, 288, 299 |
235 | Sodium oxybate | 1件: Sodium oxybate; | D05866 |
- |
- |
3件: 6, 120, 149 |
236 | Solifenacin | 2件: Solifenacin; Solifenacin succinate (vesicare); | D01269 D08522 |
1件: CHRM3 |
9件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction |
1件: 6 |
237 | Sulfate ion | - | - |
- |
- |
22件: 2, 6, 11, 13, 26, 34, 36, 46, 49, 60, 61, 64, 66, 79, 86, 96, 222, 226, 265, 296, 297, 299 |
238 | Sumanirole | 1件: Sumanirole; | - |
- |
- |
1件: 6 |
239 | Suvorexant | 1件: Suvorexant; | D10082 |
2件: HCRTR1, HCRTR2 |
1件: Neuroactive ligand-receptor interaction |
3件: 5, 6, 13 |
240 | Tadalafil | 11件: Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); Fdc macitentan/tadalafil; Tadalafil; Tadalafil 20 mg; Tadalafil 20 mg film-coated tablets; Tadalafil 40 mg; Tadalafil and ambrisentan upfront combination therapy; Tadalafil and sildenafil; Tadalafil oral suspension; Tadalafil, placebo; Tadalafil- tablet or oral suspension; | D02008 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
6件: 6, 51, 75, 84, 86, 113 |
241 | Talampanel | 1件: Talampanel; | D02696 |
4件: GRIA1, GRIA2, GRIA3, GRIA4 |
13件: Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Transcriptional misregulation in cancer, cAMP signaling pathway |
2件: 2, 6 |
242 | Tavapadon | - | D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
243 | Technetium Tc-99m exametazime | - | D02284 |
- |
- |
1件: 6 |
244 | Terazosin | 2件: Terazosin; Terazosin 5 mg; | D00610 D08569 |
3件: ADRA1A, ADRA1B, ADRA1D |
7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 6 |
245 | Tesofensine | 3件: 1. tesofensine (ns 2330); Tesofensine; Tesofensine/metoprolol; | - |
- |
- |
2件: 6, 193 |
246 | Tolcapone | 1件: Tolcapone; | D00786 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
3件: 6, 28, 127 |
247 | Topiramate | 2件: Topiramate; Topiramate (drug); | D00537 |
36件: CA2, CA4, CACNA1C, CACNA1D, CACNA1F, CACNA1S, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
48件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Arrhythmogenic right ventricular cardiomyopathy (ARVC), Bile secretion, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Collecting duct acid secretion, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term depression, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Nitrogen metabolism, Oxytocin signaling pathway, Pancreatic secretion, Proximal tubule bicarbonate reclamation, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Transcriptional misregulation in cancer, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
5件: 6, 140, 144, 156, 193 |
248 | Topramezone | - | - |
- |
- |
7件: 6, 13, 46, 50, 96, 97, 299 |
249 | Tozadenant | 5件: Tozadenant; Tozadenant (syn115) 120 mg bid; Tozadenant (syn115) 180 mg bid; Tozadenant (syn115) 240 mg bid; Tozadenant (syn115) 60 mg bid; | D10174 |
1件: ADORA2A |
7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
1件: 6 |
250 | Triamcinolone | 10件: Bladder instillation with triamcinolone acetonide; Bladder instillation without triamcinolone acetonide; Bupivacaine & triamcinolone acetonide; Intra plexus triamcinolone and bupivicaine injection; Triamcinolone; Triamcinolone acetonide; Triamcinolone acetonide and normal saline solution; Triamcinolone hexacetonid (lederspan); Triamcinolone hexacetonide; Triamcinolone hexacetonide (lederspan); | D00385 D00983 D00984 D00985 D06216 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
18件: 6, 10, 13, 35, 40, 41, 42, 43, 44, 45, 46, 56, 70, 90, 96, 97, 226, 298 |
251 | Trihexyphenidyl | 2件: Primary cervical dystonia (trihexyphenidyl); Trihexyphenidyl; | D00787 D08638 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
2件: 5, 6 |
252 | Trimethobenzamide | 2件: Trimethobenzamide; Trimethobenzamide hydrochloride; | D02733 D08643 |
- |
- |
1件: 6 |
253 | Tropicamide | 5件: 0 mg tropicamide; 0.3 mg tropicamide; 1 mg tropicamide; 3 mg tropicamide; Tropicamide; | D00397 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
2件: 6, 19 |
254 | Tyrosine | 2件: L-tyrosine; Tyrosine; | D00022 |
- |
- |
3件: 6, 86, 111 |
255 | Ubidecarenone | - | D01065 |
- |
- |
12件: 2, 5, 6, 8, 10, 46, 57, 86, 113, 193, 214, 215 |
256 | Ubiquinol | 1件: Ubiquinol; | - |
- |
- |
3件: 6, 8, 17 |
257 | Uric acid | - | - |
- |
- |
1件: 6 |
258 | Ursodeoxycholic acid | 9件: Udca (ursodeoxycholic acid); Ursodeoxycholic acid; Ursodeoxycholic acid (udca); Ursodeoxycholic acid (urso); Ursodeoxycholic acid 300mg capsule; Ursodeoxycholic acid 300mg tablet; Ursodeoxycholic acid capsules; Ursodeoxycholic acid combination of immunosuppressive agents; Ursodiol (ursodeoxycholic acid, udca); | D00734 |
1件: NR1H4 |
1件: Bile secretion |
12件: 6, 8, 20, 67, 84, 93, 94, 95, 96, 97, 234, 299 |
259 | Valerian | 1件: Valerian; | - |
- |
- |
1件: 6 |
260 | Varenicline | 2件: Varenicline; Varenicline tartrate; | D08669 |
2件: CHRNA4, CHRNB2 |
3件: Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction |
2件: 6, 18 |
261 | Venlafaxine | 3件: Efexor xl 75 mg (venlafaxine); Venlafaxine; Venlafaxine hydrochloride; | D00821 D08670 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 6, 13, 46 |
262 | Vitamin E | 8件: Coenzyme q10 with vitamin e; Omega-3 and vitamin e supplementation; Vitamin c 10mg/kg vitamin e 10 mg/kg; Vitamin e; Vitamin e - tgps; Vitamin e 800iu; Vitamin e supplement; Vitamin e/selenium; | D02331 |
- |
- |
12件: 2, 6, 13, 20, 46, 49, 90, 96, 97, 206, 299, 317 |
263 | Warfarin | 4件: S-warfarin; The generic name is warfarin and many producers will be involved; Warfarin; Warfarin 10 mg; | D00564 D01280 D08682 |
2件: NQO1, VKORC1 |
5件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
10件: 6, 8, 13, 19, 46, 49, 66, 85, 88, 96 |
264 | Water | 13件: 15 o water; 15-o labeled water; 5% glucose water solution; Dextrose, 5% in water; High water intake; Lactose in water; Pl 12185/0002 & pl 12185/0005(water for injection); Pseudoephedrine + 480 ml water; Pseudoephedrine + 50 ml water; Water; Water for injection; Water for injections; Water for injections, ep; | D00001 |
- |
- |
22件: 2, 5, 6, 13, 17, 19, 28, 35, 46, 53, 57, 63, 65, 67, 78, 84, 97, 193, 226, 271, 278, 299 |
265 | Zoledronic acid | 4件: Lonafarnib, zoledronic acid, and pravastatin; Zoledronic acid; Zoledronic acid 5mg/bag 100ml inj; Zoledronic acid monohydrate; | D01968 D06378 D06379 D08689 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
11件: 6, 13, 46, 65, 93, 95, 96, 271, 274, 299, 333 |
266 | Zolmitriptan | 1件: Zolmitriptan; | D00415 |
2件: HTR1B, HTR1D |
4件: Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
1件: 6 |
267 | Zolpidem | 4件: Zolpidem; Zolpidem first dose; Zolpidem second dose; Zolpidem tartrate; | D00706 D08690 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
2件: 5, 6 |
268 | Zonisamide | 2件: Ad-810n (zonisamide); Zonisamide; | D00538 |
8件: CACNA1G, CACNA1H, CACNA1I, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
11件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dopaminergic synapse, GnRH secretion, MAPK signaling pathway, Taste transduction, Type II diabetes mellitus |
1件: 6 |
269 | Zopiclone | 2件: Doxepin and zopiclone; Zopiclone; | D01372 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 6 |
270 | gamma-Hydroxybutyric acid | - | - |
- |
- |
3件: 6, 120, 149 |